11 Jan 2019 Research

Leukaemia: Investigating stem cells to prevent cancer

What is this research looking at?

The development of effective treatments to prevent and eradicate leukaemia requires a better understanding of the mechanisms behind malignant (harmful) transformation and disease persistence during therapy.

Importantly, leukaemia development is associated with the acquisition of abnormal metabolic features, making cancer metabolism an attractive target for new therapeutic strategies.

Metabolism is closely associated to cell functions in normal and abnormal (malignant) tissues. By measuring metabolic heterogeneity in normal tissue (haemopoietic stem cells) and in cancer (leukaemia), I will determine whether distinct cell metabolic states are functionally connected to their potential for malignant transformation and therapy resistance.

I will test if malignant transformation and therapy resistance can be prevented or attenuated by targeting their metabolic dependencies. Results from the proposed research may lead to the development of new strategies for leukaemia eradication and prevention.

What could this mean for people with leukaemia?

This project investigates the metabolic features of stem cells in a bid to find out how to prevent them turning cancerous and to reduce resistance to treatment – this may lead to the development of new strategies for leukaemia eradication and prevention.

Related posts

Lymphoma: Understanding relapse and treatment resistance

11 January 2019

Lymphoma: Understanding relapse and treatment resistance

Dr Dinis Calado, The Francis Crick Institute and Project Grant Holder

University of Southampton’s Dr Giorgia Chiodin Wins Olive Boles Innovation Award

7 November 2024

University of Southampton’s Dr Giorgia Chiodin Wins Olive Boles Innovation Award

Dr Giorgia Chiodin from the University of Southampton has been awarded the prestigious Olive Boles Innovation Award for 2024. Awarded annually to a Leukaemia UK John Goldman Fellow, this award…

1 in 4 leukaemia patients in England experiences an avoidable delay in diagnosis

18 September 2025

1 in 4 leukaemia patients in England experiences an avoidable delay in diagnosis

A first of its kind study, commissioned by Leukaemia UK, has revealed that a quarter (26%) of leukaemia patients in England experience avoidable delays in their diagnosis, resulting in a…

“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers

17 April 2024

“Every little thing is gonna be alright” – three little birds tattoo marks mum’s recovery from one of the least survivable cancers

New research by Leukaemia UK which could reduce the side-effects of treatment for acute myeloid leukaemia (AML) welcomed by family affected by the disease.   A family who was devastated when…